{"publication_id":"2b3d1eb0-8efe-4468-b234-8a534f83b06b","screening":{"identified":52,"screened":52,"excluded":0,"included":52,"included_or_retained":52,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"52 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["The corpus contains 2 direct clinical sources, 50 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.","The thesis is: Across 52 curated reference papers, the evidence base for Glp 1 shows a context-dependent profile. Positive signals appear in: longevity, mortality survival. Negative signals appear in: cardiometabolic, contextual other. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Glp 1 anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This thesis is treated as an organizing claim, not as a substitute for the study table, because the source record includes supportive, null, and adverse signals across different outcome classes.","Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.","The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.","Geroscience frames aging as a unitary biological process in which a discrete set of hallmark mechanisms — mitochondrial dysfunction, cellular senescence, deregulated nutrient sensing, stem-cell exhaustion, altered intercellular communication, and others — can be targeted to delay or compress morbidity and extend healthspan (canonical threshold anchors include Studenski 2011's 0.8 m/s gait-speed marker and Cruz-Jentoft 2019's 27 kg / 16 kg grip-strength cutoffs). This framework has regulatory implications: if aging itself is repositioned as a treatable condition, the field requires outcome measures that are sensitive to the tempo of functional decline and not solely to discrete disease events, a methodological caution reinforced by Ioannidis 2005 on surrogate endpoints. The present synthesis is anchored in GLP-1 — the proposal that glucagon-like peptide-1 receptor agonism, alone or combined with dual incretins, may shift trajectories on these aging-relevant endpoints. Across 52 curated references, however, the GLP-1 case is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and boundary conditions remain to be established.","Mechanistically, the cardiometabolic evidence in this corpus maps onto canonical GLP-1 receptor pathways including glycemic lowering, weight reduction, blood pressure decrement, and lipid modulation, which are most cleanly read in clinical RCT material such as Impact of GLP Receptor 2026 and in meta-analytic synthesis such as Rivera 2024. Crowley's case report (Crowley 2024) on lymphedema and Hashimoto 2025 on combined obesity-diabetes management extend the mechanistic substrate into adjacent cardiometabolic territory, while Fang 2026 reviews the dual GIP/GLP-1 agonist tirzepatide in obstructive sleep apnea as a downstream BMI-mediated cardiovascular lever, citing a near six-fold OSAS risk increment for every 10% BMI rise.","Within-corpus tensions on dosing and pharmacokinetics are limited to a single source, so no pairwise disagreements can be surfaced for this outcome class. By contrast, the broader corpus places cardiometabolic, body composition, and glycemic outcomes downstream of the PK envelope that Schneck 2024 establishes, and the indirectness flag functions as the integration point rather than as a contradiction. The PK finding of sustained exposure therefore reads as a permissive upstream condition rather than as direct longevity evidence, consistent with the integrating thesis that mechanistic plausibility coexists with mixed or sparse human-RCT evidence.","The corpus contains a single observational cohort study, Zietek 2016, that directly frames inflammation as a convergence point between metabolic disease and enteroendocrine biology. The study population is described as adults, and the design is observational rather than interventional, which constrains causal inference about GLP-1 signaling on inflammatory endpoints. The cited thesis foregrounds enteroendocrine cells (EEC) as a numerically sparse but hormonally rich compartment, noting they comprise approximately only 1% of the epithelium yet secrete more than 20 different peptide hormones. This anatomical and quantitative baseline establishes the cellular substrate from which downstream immune and metabolic effects of GLP-1 are hypothesized to propagate. No effect direction is recorded for inflammatory endpoints in the source, consistent with a null designation at the level of direct measurement."]}